NGM Biopharmaceuticals signed an agreement with Janssen Pharmaceuticals to discover and develop novel therapeutics for the potential treatment of type 2 diabetes and other metabolic diseases. NGM and Janssen will jointly conduct research on selected protein factors discovered by NGM using its diabetes discovery platform, with the goal of advancing drug candidates that mimic the potential glucoregulatory effects of bariatric surgery on diabetes patients. Janssen will receive an exclusive worldwide license to develop, manufacture, and commercialize compounds resulting from the collaboration.

Under the terms of the agreement, NGM will receive an up-front payment and research support for activities conducted in collaboration with Janssen. In addition, NGM is eligible to receive payments upon the achievement of certain research, development, regulatory and commercial milestones, as well as royalties on product sales.

In March 2012, NGM collaborated with Daiichi Sankyo in a similar deal to develop therapeutics that modulate beta-cell regeneration, for the treatment of type 1 and type 2 diabetes.

Previous articleGE Lab Product Lines Go to Maine Manufacturing
Next articleIbex Technologies Takes Over Bio-Research Products